MedinCell S.A. (MEDCL.PA)
EUR 16.8
(5.53%)
EUR 16.8
(5.53%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 39.5 Million EUR | -22.91% |
| 2022 | 51.24 Million EUR | 83.83% |
| 2021 | 27.87 Million EUR | 3816.53% |
| 2020 | -750 Thousand EUR | -102.95% |
| 2019 | 25.45 Million EUR | 342.65% |
| 2018 | 5.75 Million EUR | -74.1% |
| 2017 | 22.2 Million EUR | 31.54% |
| 2016 | 16.88 Million EUR | 357.98% |
| 2015 | 3.68 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q2 | 51.54 Million EUR | 0.0% |
| 2023 Q4 | 39.5 Million EUR | 0.0% |
| 2023 FY | 39.5 Million EUR | -22.91% |
| 2022 FY | 51.24 Million EUR | 83.83% |
| 2022 Q4 | 51.24 Million EUR | 0.0% |
| 2022 Q2 | 41.73 Million EUR | 0.0% |
| 2021 FY | 27.87 Million EUR | 3816.53% |
| 2021 Q2 | 13.7 Million EUR | 0.0% |
| 2021 Q4 | 27.87 Million EUR | 0.0% |
| 2020 Q2 | 19.51 Million EUR | 0.0% |
| 2020 Q4 | -750 Thousand EUR | 0.0% |
| 2020 FY | -750 Thousand EUR | -102.95% |
| 2019 FY | 25.45 Million EUR | 342.65% |
| 2019 Q2 | 16.66 Million EUR | 0.0% |
| 2019 Q4 | 25.45 Million EUR | 0.0% |
| 2018 Q4 | 5.75 Million EUR | 127.02% |
| 2018 FY | 5.75 Million EUR | -74.1% |
| 2018 Q3 | -21.28 Million EUR | -165.24% |
| 2018 Q2 | 32.62 Million EUR | 387.0% |
| 2018 Q1 | -11.36 Million EUR | -151.19% |
| 2017 Q1 | - EUR | 0.0% |
| 2017 Q3 | -8.79 Million EUR | 0.0% |
| 2017 Q4 | 22.2 Million EUR | 352.6% |
| 2017 FY | 22.2 Million EUR | 31.54% |
| 2016 FY | 16.88 Million EUR | 357.98% |
| 2015 FY | 3.68 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | -714 Thousand EUR | 5632.353% |
| ABIVAX Société Anonyme | -196.47 Million EUR | 120.105% |
| Adocia SA | 127 Thousand EUR | -31003.15% |
| Aelis Farma SA | -16.19 Million EUR | 343.954% |
| Biophytis S.A. | 2.7 Million EUR | -1361.376% |
| Advicenne S.A. | 12.17 Million EUR | -224.444% |
| genOway Société anonyme | 2.97 Million EUR | -1228.672% |
| IntegraGen SA | -709.74 Thousand EUR | 5665.489% |
| Medesis Pharma S.A. | 1.15 Million EUR | -3310.521% |
| Neovacs S.A. | -237.08 Thousand EUR | 16760.973% |
| NFL Biosciences SA | -2.27 Million EUR | 1835.644% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -806.712% |
| Quantum Genomics Société Anonyme | -830.54 Thousand EUR | 4856.017% |
| Sensorion SA | 1.37 Million EUR | -2766.084% |
| Theranexus Société Anonyme | 2.44 Million EUR | -1516.141% |
| TME Pharma N.V. | -1.07 Million EUR | 3760.89% |
| Valbiotis SA | -18.13 Million EUR | 317.768% |
| TheraVet SA | 12.78 Thousand EUR | -308863.629% |
| Valerio Therapeutics Société anonyme | 2.18 Million EUR | -1711.972% |
| argenx SE | -1.83 Billion EUR | 102.151% |
| BioSenic S.A. | 28.04 Million EUR | -40.854% |
| Celyad Oncology SA | -6.1 Million EUR | 747.345% |
| DBV Technologies S.A. | -114.95 Million USD | 134.362% |
| Galapagos NV | -157.2 Million EUR | 125.127% |
| Genfit S.A. | -7.61 Million EUR | 618.999% |
| GeNeuro SA | 5.91 Million EUR | -568.33% |
| Hyloris Pharmaceuticals SA | -25.11 Million EUR | 257.299% |
| Innate Pharma S.A. | -30.71 Million EUR | 228.617% |
| Inventiva S.A. | 10.48 Million EUR | -276.595% |
| MaaT Pharma SA | -10.2 Million EUR | 487.075% |
| Nanobiotix S.A. | -24.71 Million EUR | 259.807% |
| Onward Medical N.V. | -12.89 Million EUR | 406.352% |
| Oryzon Genomics S.A. | 1.43 Million EUR | -2661.663% |
| OSE Immunotherapeutics SA | 27.12 Million EUR | -45.604% |
| Oxurion NV | 10.71 Million EUR | -268.824% |
| Pharming Group N.V. | 99.4 Million EUR | 60.261% |
| Poxel S.A. | 44.55 Million EUR | 11.351% |
| GenSight Biologics S.A. | 16.29 Million EUR | -142.427% |
| Transgene SA | -14.4 Million EUR | 374.141% |
| Financière de Tubize SA | 78.62 Million EUR | 49.76% |
| UCB SA | 2.17 Billion EUR | 98.186% |
| Valneva SE | 82.73 Million EUR | 52.257% |
| Vivoryon Therapeutics N.V. | -18.52 Million EUR | 313.242% |